Arsenal buys BresMed to build strategy consulting group

By Vassia Barba contact

- Last updated on GMT

(Image: Getty/marchmeena29)
(Image: Getty/marchmeena29)

Related tags: Ppd, Consulting, Strategic management

Arsenal has acquired BresMed to form a value demonstration company intended to support biopharmaceutical clients through strategy, evidence and communication tools.

BresMed Health Solutions is a provider of health economic research, communications, and consulting services, operating with offices in the US, the UK, Ireland, the Netherlands, and India to support pharmaceutical companies at all stages of development.

The consulting company was acquired by private equity firm Arsenal Capital Partners, as a first step in the latter’s efforts to build a new ‘value demonstration’ company.

According to the firm, the new company will aim to support biopharmaceutical clients with the strategy, evidence and communication tools to help maximize the value of their products.

Support in substantiation and conveying of pharmaceutical products’ value answers a ‘critical’ need in drug development and one of healthcare’s ‘most pressing’ challenges, commented Gene Gorbach, an Arsenal investment partner.

On his side, Nic Brereton, BresMed’s CEO stated that the establishment of the new company is expected to have a ‘transformational’ impact on the speed, efficiency and quality of evidence required to support industry decision making.

Jon Williams, who most recently was the CEO of Evidera, a unit of the contract research organization (CRO), PPD​, will take over the management of the new company established by Arsenal.

Related topics: Clinical Development, Clinical evolution

Related news

Follow us

Products

View more

Webinars